# iLoF - Intelligent Lab on Fiber

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ilof-intelligent-lab-on-fiber

- Industry: Biotechnology
- Headquarters: London, UK
- Website: www.ilof.tech
- Total disclosed funding: $6.4M
- Latest round: Seed (Jan 2, 2022)
- Investors on record: 9

## About

iLoF is a UK-based technology company that specializes in optical fingerprinting and artificial intelligence, developing innovative solutions for non-invasive blood-based patient screening and clinical trial stratification.Founded in 2019 in London, UK, iLoF - Intelligent Lab on Fiber Limited focuses on applying photonics and AI technologies to enhance healthcare solutions. The company has secured a total of USD 4.71 mn through various funding rounds, including a recent GRANT of USD 0.90 mn from the European Regional Development Fund on October 22, 2024. Its founders include Joana Paiva, Luis Valente, Mariana Da Silva, Mehak M, and Paula Sampaio, with Luis Valente serving as CEO.iLoF specializes in a cloud-based platform leveraging optical fingerprinting technologies powered by photonics and AI. Their primary product is a non-invasive blood-based screening test designed to stratify patients for clinical trials, addressing heterogeneity in clinical populations. Targeting clients such as pharmaceutical companies and healthcare providers, iLoF operates in key markets, including the United States, United Kingdom, and Portugal, impacting drug development in areas like Alzheimer’s disease, cancer, and COVID-19.iLoF generates revenue through partnerships and subscription-based agreements with pharmaceutical companies and clinical research organizations. Clients access the iLoF platform for patient screening, data analysis, and reporting, utilizing the proprietary optical fingerprinting technology for efficient drug development.With the recent funding from Hamamatsu Ventures, iLoF aims to expedite the implementation of its Optomics technology and extend its market reach into the US and Japan. This strategic move is expected to broaden their client base and enhance service offerings as they continue to innovate in patient screening and clinical trial efficiency.

## Funding rounds

- Seed, Jan 2, 2022, $5.4M — M12, Faber Ventures, Berggruen Holdings, Lunar Ventures, Fluxunit, Quiet Capital, Alter Venture Partners, re.Mind Capital
- Seed, Jul 15, 2020, $1M — Mayfield Fund, M12

## Investors

- Mayfield Fund (https://capitalatlas.ai/funds/mayfield-fund) — Seed
- M12 (https://capitalatlas.ai/funds/m12) — Seed
- Faber Ventures (https://capitalatlas.ai/funds/faber-ventures) — Seed
- Berggruen Holdings (https://capitalatlas.ai/funds/berggruen-holdings) — Seed
- Lunar Ventures (https://capitalatlas.ai/funds/lunar-ventures) — Seed
- Fluxunit (https://capitalatlas.ai/funds/fluxunit) — Seed
- Quiet Capital (https://capitalatlas.ai/funds/quiet-capital) — Seed
- Alter Venture Partners (https://capitalatlas.ai/funds/alter-venture-partners) — Seed
- re.Mind Capital (https://capitalatlas.ai/funds/re-mind-capital) — Seed